BACKGROUND: Hemodialysis (HD) patients have a greatly increased risk of cardiovascular morbidity and mortality. For this reason, attempts are often made to normalize hyperhomocysteinemia. This randomized prospective study sought to determine which risk factors are predictors of mortality and whether high doses of folates or 5-methyltetrahydrofolate (5-MTHF) could improve hyperhomocysteinemia and survival in HD patients. METHODS:341 patients were divided into two groups: group A was treated with 50 mg i.v. 5-MTHF, and group B was treated with 5 mg/day oral folic acid. Both groups received i.v. vitamin B(6) and B(12). By dividing patients into C-reactive protein (CRP) quartiles, group A had the highest survival for CRP <12 mg/l, whereas no survival difference was found for group B. CRP was the only predictive risk factor for death (RR 1.17, range 1.04-1.30, p = 0.02). Dialysis age, hyperhomocysteinemia, methylenetetrahydrofolate reductase polymorphism, albumin, lipoprotein (a) and folate did not influence mortality risk. Survival in group A was higher than that in group B, namely 36.2 +/- 20.9 vs. 26.1 +/- 22.2 months (p = 0.003). RESULTS: Our results suggest that CRP, but not hyperhomocysteinemia, is the main risk factor for mortality in HD patients receiving vitamin supplements. Intravenous 5-MTHF seems to improve survival in HD patients independent from homocysteine lowering. Copyright 2008 S. Karger AG, Basel.
RCT Entities:
BACKGROUND: Hemodialysis (HD) patients have a greatly increased risk of cardiovascular morbidity and mortality. For this reason, attempts are often made to normalize hyperhomocysteinemia. This randomized prospective study sought to determine which risk factors are predictors of mortality and whether high doses of folates or 5-methyltetrahydrofolate (5-MTHF) could improve hyperhomocysteinemiaand survival in HDpatients. METHODS: 341 patients were divided into two groups: group A was treated with 50 mg i.v. 5-MTHF, and group B was treated with 5 mg/day oral folic acid. Both groups received i.v. vitamin B(6) andB(12). By dividing patients into C-reactive protein (CRP) quartiles, group A had the highest survival for CRP <12 mg/l, whereas no survival difference was found for group B. CRP was the only predictive risk factor for death (RR 1.17, range 1.04-1.30, p = 0.02). Dialysis age, hyperhomocysteinemia, methylenetetrahydrofolate reductase polymorphism, albumin, lipoprotein (a) and folate did not influence mortality risk. Survival in group A was higher than that in group B, namely 36.2 +/- 20.9 vs. 26.1 +/- 22.2 months (p = 0.003). RESULTS: Our results suggest that CRP, but not hyperhomocysteinemia, is the main risk factor for mortality in HDpatients receiving vitamin supplements. Intravenous 5-MTHF seems to improve survival in HDpatients independent from homocysteine lowering. Copyright 2008 S. Karger AG, Basel.
Authors: C van Guldener; M J Janssen; J Lambert; P M ter Wee; C Jakobs; A J Donker; C D Stehouwer Journal: Nephrol Dial Transplant Date: 1998-01 Impact factor: 5.992
Authors: Ajith P Nair; Dmitry Nemirovsky; Michael Kim; Eliza B Geer; Michael E Farkouh; Jonathan Winston; Jonathan L Halperin; Michael J Robbins Journal: Mt Sinai J Med Date: 2005-11
Authors: O Nygård; S E Vollset; H Refsum; I Stensvold; A Tverdal; J E Nordrehaug; M Ueland; G Kvåle Journal: JAMA Date: 1995-11-15 Impact factor: 56.272
Authors: Cornelia M Ulrich; Mary Playdon; Rama Kiblawi; Andreana N Holowatyj; Biljana Gigic; Stefanie Brezina; Anne J M R Geijsen; Jennifer Ose; Tengda Lin; Sheetal Hardikar; Caroline Himbert; Christy A Warby; Jürgen Böhm; Martijn J L Bours; Fränzel J B van Duijnhoven; Tanja Gumpenberger; Dieuwertje E Kok; Janna L Koole; Eline H van Roekel; Petra Schrotz-King; Arve Ulvik; Andrea Gsur; Nina Habermann; Matty P Weijenberg; Per Magne Ueland; Martin Schneider; Alexis Ulrich Journal: Br J Nutr Date: 2020-02-05 Impact factor: 3.718
Authors: Vania Cuna; Viola Menghi; Giorgia Comai; Maria Cappuccilli; Giuseppe Cianciolo; Concettina Raimondi; Francesco Grammatico; Gabriele Donati; Olga Baraldi; Irene Capelli; Gaetano LA Manna Journal: In Vivo Date: 2017 Nov-Dec Impact factor: 2.155
Authors: Meg J Jardine; Amy Kang; Sophia Zoungas; Sankar D Navaneethan; Toshiharu Ninomiya; Sagar U Nigwekar; Martin P Gallagher; Alan Cass; Giovanni Strippoli; Vlado Perkovic Journal: BMJ Date: 2012-06-13
Authors: Vania Cuna; Giorgia Comai; Maria Cappuccilli; Olga Baraldi; Irene Capelli; Matteo De Liberali; Lorenzo Gasperoni; Diletta Conte; Matteo Ravaioli; Antonio D Pinna; Gaetano La Manna Journal: Med Sci Monit Date: 2017-09-18
Authors: Giuseppe Cianciolo; Antonio De Pascalis; Luca Di Lullo; Claudio Ronco; Chiara Zannini; Gaetano La Manna Journal: Cardiorenal Med Date: 2017-06-21 Impact factor: 2.041